NYSE Arca · CATX
Perspective Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CATX: Nov 9, 2026
Perspective Therapeutics, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.24. The reported EPS for the same quarter last year was $-0.35.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.24 | $-0.23 | $-0.27 | 8 |
| Dec 2026 | $-0.26 | $-0.24 | $-0.31 | 7 |
| Mar 2027 | $-0.27 | $-0.25 | $-0.34 | 5 |
| Jun 2027 | $-0.28 | $-0.26 | $-0.35 | 5 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · RTTNews- Fintel · Oct 23, 11:19 AM EDTPerspective Therapeutics, Inc. Announces Interim Phase 1/2a Results for [212Pb]VMT-α-NETPerspective Therapeutics, Inc. announced new interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). Presented at the European So
- Zacks · Oct 9, 6:42 AM EDTStrength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- RTTNews · Oct 8, 6:39 AM EDTFDA Grants Fast Track To Perspective Therapeutics' PSV359(RTTNews) – Perspective Therapeutics, Inc. (CATX), a radiopharmaceutical development company, said the FDA granted Fast Track Designation for [212Pb]PSV359 for adults with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors (SFTs).
- Zacks · Aug 6, 10:35 PM EDTProfound Medical (PROF) Q2 Earnings Surpass EstimatesProfound Medical (PROF) delivered earnings and revenue surprises of +218.18% and -55.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 4, 9:40 AM EDTAre Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
- Zacks · Aug 3, 10:34 AM EDT4 Biotech Stocks Likely to Outpace Q2 Earnings EstimatesMedical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
- Zacks · Jul 29, 9:55 AM EDTPerspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock NowAfter losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- RTTNews · Jul 28, 11:42 AM EDTPerspective Wins EU Orphan Drug Status For Lead-212 VMT-alpha-NET In Gastroenteropancreatic Tumors(RTTNews) – Perspective Therapeutics, Inc. (CATX), a radiopharmaceutical company developing targeted cancer therapies, on Tuesday announced that the European Commission has granted orphan medicinal product designation to Lead-212 VMT-alpha-NET for the treatment of gastroenteropan
- Zacks · Jul 16, 9:40 AM EDTIs Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
- Zacks · May 7, 7:05 PM EDT4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Apr 21, 1:40 AM EDTWedbush Reiterates Perspective Therapeutics At Outperform With $11 Price Target(RTTNews) – Wedbush analyst David Nierengarten on Monday reiterated an Outperform rating and a 12-month price target of $11 for Perspective Therapeutics, Inc. (CATX), a clinical-stage radiopharmaceutical company.
- Fintel · Feb 19, 7:02 AM ESTPiper Sandler Initiates Coverage of Perspective Therapeutics (CATX) with Overweight RecommendationFintel reports that on February 19, 2026, Piper Sandler initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with a Overweight recommendation. Analyst Price Forecast Suggests 148.41% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Perspective Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.